Pyramid Analytics expands AI-driven Decision Intelligence with new OpenAI integration
Pyramid Analytics (Pyramid), a leading business analytics and decision intelligence provider, announced today at the Gartner Data & Analytics Summit in Orlando, Florida, that the Pyramid 2023 release extends its already category-leading, AI-driven augmented capabilities with the integration of GPT (generative pre-trained transformer) AI technology from OpenAI—the company behind ChatGPT and DALL-E 2—throughout the platform, interoperating with its deep set of current AI technologies.
The release harnesses the new GPT AI engines to drive complex logic, data science, and machine learning code generation; AI-driven storytelling capabilities; and even AI-assisted design templates and colors. The effort extends Pyramid’s broader vision to enable and drive adoption across the enterprise by empowering all users to solve data-centric business problems through no-code and AI-assisted analytics and decision intelligence.
Key facts about Pyramid’s OpenAI integration
OpenAI is integrated throughout the Decision Intelligence Platform—including the data preparation, data science, the business analytics and spreadsheet modules, and the storyboard and publication designer modules.
- In data preparation: OpenAI can be used to generate SQL, DAX, and MDX code automatically for complex data extraction queries.
- In data science: OpenAI can be used to generate Python and R code automatically to drive machine learning logic.
- In spreadsheets: OpenAI can be used to build spreadsheet formulas for users constructing business models.
- In storyboarding and publications: OpenAI can be used to generate designs for content and graphics.
Separately, OpenAI can be used with existing natural language querying (NLQ) engines to drive and enhance broader insights on enterprise-specific data, ultimately improving the existing tools for delivering automated storytelling and textual analysis.
Market recognition
Pyramid has long been recognized as an innovator in the decision intelligence and analytics space. The company’s Decision Intelligence Platform was ranked #1 —by leading analyst firm Gartner—for “Augmented Analytics” in the 2022 Gartner Analytics and Business Intelligence (ABI) Critical Capabilities report.
Other leading analysts—such as 451 Research , Ventana Research , Dresner Advisory Services , and BARC —recognize Pyramid for its platform-based approach to no-code capabilities and AI/augmented analytics to enable all user types to drive sophisticated analytics easily. Critically, Pyramid’s existing augmented capabilities (NLQ, Chatbot, Smart Insights, Smart Model, Auto Discovery, Fill in the Blanks, Explain, etc.) uniquely operate directly on enterprise data without data duplication, custom models, proprietary data layers, or specialized data treatments.
Demos
Click here to schedule a demo of the Pyramid Decision Intelligence Platform and to learn more about OpenAI on the platform.
Quotes
Avi Perez, CTO and Co-Founder, Pyramid Analytics : “By integrating OpenAI throughout the Pyramid Decision Intelligence Platform, we are extending our existing AI and augmented capabilities with the latest generative AI tech, transforming—and simplifying—the decision-making experience further. As a no-code/low-code platform, Pyramid is designed to extend advanced analytics—from descriptive to predictive to prescriptive—for non-technical businesspeople, allowing them to make informed decisions that drive business outcomes.”
Omri Kohl, CEO and Co-Founder, Pyramid Analytics: “At Pyramid, we believe the key to widespread adoption of data analytics requires an analytics experience that meets different people’s needs, regardless of their technical skills or analytics aptitude. By strategically integrating generative AI technologies like OpenAI, we are taking our AI vision to the next level.”
About Pyramid Analytics
Pyramid Analytics is the next generation of decision intelligence. The award-winning Pyramid Decision Intelligence Platform empowers people with augmented, automated, and collaborative insights that simplify and guide the use of data in decision-making. Critically, the Pyramid Platform operates directly on any data, enabling governed self-service for any person; and meeting analytical needs in a no-code environment without data extraction, ingestion, and duplication. It combines data prep, business analytics, and data science into one frictionless platform to empower anyone with intelligent decision-making. This enables a strategic, enterprise-wide approach to business intelligence and analytics, from the simple to the sophisticated. Schedule a demo today.
Pyramid Analytics is incorporated in Amsterdam and has regional headquarters in global innovation and business centers, including London, New York City, and Tel Aviv. Our team lives worldwide because geography should not hinder talent and opportunity. Investors include H.I.G. Growth Partners, Jerusalem Venture Partners (JVP), Sequoia Capital, and Viola Growth. Learn more at Pyramid Analytics.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230320005287/en/
Contact information
Pyramid Analytics
Pete Vomocil
SVP, Global Marketing, Pyramid Analytics
pr@pyramidanalytics.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 14:00:00 EET | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreement were not disclosed. “This new agreement builds upon our recent co-development collaboration with Acepodia, which has focused on the evaluation and selection
Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 12:08:00 EET | Press release
Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played
Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 11:44:00 EET | Press release
At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will
Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 11:00:00 EET | Press release
Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE. “Insurance is an industry where the stakes of using AI are particularly high: the decisions can affect millions of people. Allianz and Anthropic both take that very seriously, and we look forward to working together to make insurance better for those w
MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 08:00:00 EET | Press release
MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind, placebo-controlled study designed to confirm the promising efficacy signals and favorable safety profile previously observed in MH002’s Phase 2a studies. MH002, a rationally designed live microbial consortium, is the most advanced Live Biotherapeutic Product (LBP) of its kind, targeting disease-specific mechanisms through a synergistic combination of
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom